ZENTALIS PHARMACEUTICALS INC (ZNTL) Stock Balance Sheet
NASDAQ:ZNTL - Nasdaq - US98943L1070 - Common Stock - Currency: USD
| MRQ (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 41.93M | 33.90M | 28.04M | 43.10M | 59.70M | |||
| Marketable Securities | 290.52M | 337.18M | 454.88M | 394.30M | 280.20M | |||
| Receivables | 2.74M | 7.94M | 3.34M | 6.40M | 0.00 | |||
| Other Current Assets | 7.69M | 7.04M | 10.46M | 8.20M | 10.80M | |||
| Total Current Assets | 342.88M | 386.07M | 496.72M | 451.90M | 350.80M | |||
| Non-Current Assets | ||||||||
| PPE Net | 35.17M | 37.23M | 41.73M | 50.10M | 52.80M | |||
| Investments And Advances | N/A | N/A | 0.00 | 21.20M | 37.50M | |||
| Goodwill | N/A | 0.00 | 3.74M | 3.70M | 3.70M | |||
| Intangibles | N/A | N/A | N/A | N/A | 0.00 | |||
| Other Non-Current Assets | 5.97M | 7.04M | 9.50M | 12.40M | 9.70M | |||
| Total Non-Current Assets | 41.14M | 44.27M | 54.97M | 87.40M | 103.70M | |||
| TOTAL ASSETS | 384.02M | 430.34M | 551.69M | 539.30M | 454.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 41.66M | 45.29M | 54.16M | 45.00M | 31.40M | |||
| Accounts Payable | 7.77M | 7.44M | 14.93M | 11.20M | 11.60M | |||
| Other Current Liabilities | N/A | 0.00 | 281.00K | 400.00K | 1.00M | |||
| Total Current Liabilities | 49.43M | 52.73M | 69.37M | 56.60M | 43.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | 0.00 | 900.00K | 1.60M | |||
| Other Non-Current Liabilities | 39.21M | 40.43M | 44.93M | 47.80M | 44.50M | |||
| Total Non-Current Liabilities | 39.21M | 40.43M | 45.04M | 48.90M | 46.70M | |||
| TOTAL LIABILITIES | 88.64M | 93.15M | 114.40M | 105.50M | 90.60M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -1.10B | -1.05B | -888.56M | -596.40M | -359.60M | |||
| Additional Paid In Capital | 1.40B | 1.39B | 1.32B | 1.03B | 723.60M | |||
| Minority Interest | N/A | 0.00 | 107.00K | 200.00K | 500.00K | |||
| Common Shares | 72.00K | 71.00K | 70.00K | 100.00K | 0.00 | |||
| Other Shareholders' Equity | 358.00K | 558.00K | 2.19M | N/A | N/A | |||
| Shares Outstanding | 71.95M | 71.28M | 70.77M | 59.30M | 45.50M | |||
| Tangible Book Value per Share | 4.11 | 4.73 | 6.13 | 7.25 | 7.92 | |||
| Total Shareholders' Equity | 295.38M | 337.19M | 437.28M | 433.80M | 364.00M | |||
| TOTAL LIABILITIES AND EQUITY | 384.02M | 430.34M | 551.69M | 539.30M | 454.50M | |||
| Statistics | ||||||||
| Current Ratio | 6.94 | 7.32 | 7.16 | 7.98 | 7.99 | |||
| Return On Assets (ROA) | -58.38% | -38.54% | -52.96% | -43.91% | -34.92% | |||
| Return On Equity (ROE) | -75.90% | -49.18% | -66.82% | -54.59% | -43.61% | |||
All data in USD , ROIC based on taxRate of 0.21